The U.S. Food and Drug Administration approved tislelizumab-jsgr (Tevimbra) in combination with chemotherapy as a first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinomas whose tumors express PD-L1.
FBI Reform - fbireform.comFBI Reform - fbireform.com - The News And Times